The Efficacy and Safety of Adding Olanzapine to Triple Drugs Regimen to Prevent Chemotherapy-induced Nausea and Vomiting: A systematic Review and Meta-analysis of RCTs

Sharanabasayyaswamy B. Hiremath, Srinivas L. Devendrappa

Abstract


Chemotherapy-induced nausea and vomiting (CINV) is a complication of highly emetogenic chemotherapy (HEC) agents. The present meta-analysis was conducted to quantify and analyze the efficacy and safety of adding olanzapine to a Neurokinin Receptor Antagonist (NKRA) based triple-drug regimen in preventing HEC-induced CINV. Electronic database searches in PUBMED and Cochrane library was conducted using MeSH search terms “olanzapine” and “chemotherapy-induced nausea and vomiting.” Randomized or cross-over trials comparing the efficacy of “olanzapine + NKRA based triple-drug regimen” vs. “placebo + NKRA based triple-drug regimen” in patients of age > 18 years with any malignancy receiving HEC were considered under inclusion criteria. Complete Response (CR) for the delayed (25–120 h) phase of CINV in patients receiving HEC agents was the primary outcome measure analyzed. Outcome measures were estimated by calculating the Risk Difference (RD) values and their 95% Confidence Intervals (CI). The Mantel-Haenszel method and both fixed and random effect models were used in the analysis by Revman 5.4.1 soft- ware. An additional 14% (RD: 0.14, 95% CI: 0.09 to 0.19) of patients treated with olanzapine + triple-drug regimen had a statistically significant higher CR in the delayed phase when compared to placebo + NKRA-based triple-drug regimen. Adding olanzapine at 10mg to the triple-drug regimen significantly improves delayed phase CR rates by 16% and delayed phase ‘no significant nausea’ rates by 30%. Results need to be interpreted cautiously in the background of response variations and limited trials included in our analysis


Keywords


Olanzapine, chemotherapy-induced nausea vomiting, meta-analysis

Full Text:

PDF

References


Zhou JG, Huang L, Jin SH, Xu C, Frey B, Ma H, et al. Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020;5:e000621.

Herrstedt J, Roila F, Warr D, Celio L, Navari RM, Hesketh PJ, et al. 2016 Updated MASCC/ESMO consensus recommendations: preventing nausea and vomiting following high emetic risk chemotherapy. Supportive Care in Cancer. 2017;25:277-288.

Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology. 2017;35:3240-3261.

Shi Q, Li W, Li H, Le Q, Liu S, Zong S, et al. Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison. Oncotarget. 2016;7:24402-24414.

Jin Y, Jin G, Zhao J, Jiang C, Zhao L, Jiang Y, et al. Clinical Observation of Gene Polymorphism of Olanzapine or Aprepitant in Prevention of CINV. Pharmgenomics Pers Med. 2021;14:867-875.

Hiu L, Chow R, DeAngelis C, Lock M, Simone CB 2nd. Secondary and cumulative meta-analysis of olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness?. Ann Palliat Med. 2021;10:2540-2547.

Chow R, Herrstedt J, Aapro M, Chiu L, Lam H, Prsic E, et al. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Supportive Care in Cancer. 2021;29:3439-3459.

Zhang Z, Zhang Y, Chen G, Hong S, Yang Y, Fang W, et al. Olanzapine‐based triple regimens versus neurokinin‐1 receptor antagonist‐based triple regimens in preventing chemotherapy‐induced nausea and vomiting associated with highly emetogenic chemotherapy: A network meta‐analysis. The oncologist. 2018 ;23:603-616.

Yokoe T, Hayashida T, Nagayama A, Nakashoji A, Maeda H, Seki T, et al. Effectiveness of antiemetic regimens for highly emetogenic chemotherapy‐induced nausea and vomiting: a systematic review and network meta‐analysis. The oncologist. 2019;24:e347-357.

Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 2020;21:242-249.

Yeo W, Lau TK, Li L, Lai KT, Pang E, Cheung M, et al. A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. The Breast. 2020;50:30-38.

Clemons M, Dranitsaris G, Sienkiewicz M, Sehdev S, Ng T, Robinson A, et al. A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting. The Breast. 2020;54:278-285.

Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D. Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O trial. Biology of Blood and Marrow Transplantation. 2018;24:2065-2071.

Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016;375:134-142.

Mizukami N, Yamauchi M, Koike K, Watanabe A, Ichihara K, Masumori N, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. Journal of pain and symptom management. 2014;47:542-550.

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

Shumway N, Terrazzino S, Jones C. A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting. Journal of Pain Management. 2015;8:233-241.

Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. The journal of supportive oncology. 2011;9:188-195.

Pehalajani JK, Babu KG, Lokanatha D, Jacob LA, Babu MS, Lokesh KN, et al. A prospective phase III randomized study to evaluate the efficacy of olanzapine for prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC). Annals of Oncology. 2018;29:ix129.

Babu G, Saldanha SC, Kuntegowdanahalli Chinnagiriyappa L, Jacob LA, Mallekavu SB, Dasappa L, et al. The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India. Chemother Res Pract. 2016;2016:3439707.

van der Vorst MJ, Neefjes EC, Konings IR, Verheul HM. Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials. Support Care Cancer. 2015;23:2499-2506.




DOI: https://doi.org/10.15416/pcpr.v7i2.37936

Refbacks

  • There are currently no refbacks.


                                                                         
Pharmacology and Clinical Pharmacy Research is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
 
                                                                      VIEW VISITOR STATS